health $wellness blog

21st century is the era of technological advancements in artificial intelligence (AI) and deep learning. People around the globe are able to access any information at their fingertips. Medical information and healthcare have also gained an ample amount of importance in the tech world. Recently, OpenAI Inc. launched a new chatbot, called ChatGPT that interacts in a conversational way and its dialogue format makes it user-friendly and fast. The current paper is yet to appear in Diabetes & Metabolic Syndrome: Clinical Research & Reviews, aimed to explore the current position and the accuracy of currently available version of ChatGPT in relation to healthcare and medical research. Raju Vaishya and team searched different databases and found 29 results in PubMed and 9 results in Scopus database., in English language. In addition, they (RV, AM) interacted with ChatGPT multiple times to review the accuracy of 20 responses to various medical questions. The researchers found that us...

Laser therapy lowers Dentin Hypersensitivity in Periodontally Compromised Patients Undergoing Orthodontic Treatment suggests a new study published in the Journal of Clinical Medicine Patients with severe periodontal breakdown have a high risk of pathologic tooth migration due to excessive masticatory forces, typically displaying proclination of incisors and dispersed spaces among anterior teeth segments. Nowadays, an increasing number of middle-aged populations with periodontal problems seek orthodontic care after inflammation control for better oral function and aesthetics. Current evidence supports that orthodontic treatment could benefit periodontal health by facilitating occlusal force redistribution and equilibrium under the prerequisite of achieving an inflammation-remitted and stabilized periodontal condition. Sustaining a fully controlled periodontal inflammation is extremely important for periodontally compromised patients during and after orthodontic treatment [8]. Althoug...

Four-factor prothrombin complex concentrate fails to reduce blood product consumption and raises thromboembolic events in trauma patients suggests a new study published in the JAMA A study was done to investigate the efficacy and safety of 4F-PCC administration in patients at risk of massive transfusion. Double-blind, randomized, placebo-controlled superiority trial in 12 French designated level I trauma centers from December 29, 2017, to August 31, 2021, involving consecutive patients with trauma at risk of massive transfusion. Follow-up was completed on August 31, 2021. Intravenous administration of 1 mL/kg of 4F-PCC (25 IU of factor IX/kg) vs 1 mL/kg of saline solution (placebo). Patients, investigators, and data analysts were blinded to treatment assignment. All patients received early ratio-based transfusion (packed red blood cells:fresh frozen plasma ratio of 1:1 to 2:1) and were treated according to European traumatic hemorrhage guidelines. The primary outcome was 24-hour ...

New Delhi:  Revenue of private hospitals will grow 10-11 percent in financial year 2022-23 and 2023-24, supported by increasing domestic demand and pick-up in medical tourism,  says a report. According to the Crisil Ratings report, revenue of private hospitals will grow on the back of healthy bed occupancy and sustenance of high average revenue per occupied bed ( ARPOB) . In FY22, private hospitals had reported an all-time high operating profitability of 19 percent due to a surge in treatment during the second wave of the COVID-19 pandemic, which also pushed up occupancy levels, and, later, pent-up demand for elective surgeries, it said. "Growing health awareness, especially after Covid-19, leading to increase in domestic demand together with recovery in medical tourism, will ensure bed occupancy being maintained at almost similar levels of 60 percent (past five fiscals average) even as bed addition continues," Crisil Ratings Senior Director Anuj Sethi said. Sethi...

The Medical Termination of Pregnancy Regulations, 2003 Published vide Notification G.S.R. 486(E), dated 13.6.2003, published in the Gazette of India, Extraordinary, Part 2, Section 3(i), dated 13.6.2003 1. Short title, extent and commencement .- (1) These regulations may be called The Medical Termination of Pregnancy Regulations, 2003. (2) They extend to all the Union Territories. (3) They shall come into force on the date of their publication in the Official Gazette. 2. Definitions . - In these regulations, unless the context otherwise requires,- (a) "Act" means the Medical Termination of Pregnancy Act, 1971 (34 of 1971); (b) "Admission Register" means the register maintained under regulation 5; (c) "Chief Medical Officer" means the Chief Medical Officer of a District by whatever name called; (d) "Form" means a form appended to these regulations; (e) "Hospital" means a hospital established or maintained by the Central Gover...

Frankfurt : Bayer said the focus of its drug research would shift away from women's health , a traditional pillar of Germany's largest drugmaker, to hone in on neurology, rare diseases and immunology . "When it comes to research and the subsequent clinical phases, we will no longer have an explicit focus on women's health," the head of Bayer's pharmaceuticals unit, Stefan Oelrich, told Reuters on Friday. Bayer, the maker of the Yasmin brand of birth-control pills and the Mirena intrauterine device, added it would nevertheless continue to pursue the development of non-hormonal menopausal symptoms relief elinzanetant as one of its four most promising pharma products. Read also: Bayer concludes acquisition of Blackford Analysis The shifted focus comes as Bayer is due to have a change at the top in June. Incoming CEO Bill Anderson will have to deal with thousands of lawsuits claiming the Roundup weedkiller causes cancer, an underwhelming drug developm...

Cambridge : Moderna, Inc. and Generation Bio Co. have announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines. Under the terms of the agreement, Moderna may advance two immune cell programs, each of which may use a jointly developed ctLNP to deliver ceDNA. In addition, Moderna may advance two liver programs, each of which may use a liver-targeted ctLNP developed by Generation Bio to deliver ceDNA. Moderna retains an option to license a third program for either immune cells or the liver. Generation Bio will receive a $40 million upfront cash payment and a $36 million equity inv...